Aastha Pal

Aastha Pal

Auto-generated profile, based on publicly available information

Aastha Pal

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
STStefano Testa
Stefano Testa
APAastha Pal
Aastha Pal
ASAjay Subramanian
Ajay Subramanian
SVSushama Varma
Sushama Varma
JTJack Pengfei Tang
Jack Pengfei Tang
EMEverett J. Moding
Everett J. Moding
Summary: The FDA approval of T cell receptor-engineered T cells (TCR-T) for synovial sarcoma demonstrates the potential for adoptive T cell therapies (ACTs) in solid tumors. However, the paucity of tumor-specific targets without expression in normal tissues remains a major bottleneck, especially in rare cancer subtypes. Here, we present a comprehensive computational pipeline called SCAN-ACT that leverages single cell RNA sequencing and multi-omics data from tumor and normal tissues to nominate and prioritize targets for both chimeric antigen receptor (CAR)- and TCR-T cells. For surface membrane targets, SCAN-ACT proposes target pairs for bispecific Boolean logic-gated CAR T cells. For peptide-MHC targets, SCAN-ACT proposes intracellular peptides bound to a diverse set of human leukocyte antigens. We applied the SCAN-ACT pipeline to soft tissue sarcoma (STS), analyzing 986,749 single cells to identify and prioritize 395 monospecific CAR-T targets, 14,192 bispecific CAR-T targets, and 5,020 peptide-MHC targets for TCR-T cells. Selected targets were validated experimentally by protein expression and for peptide-MHC binding. Proposed targets and target pairs reflected the mesenchymal, neuronal, and hematopoietic ontogeny of STS. This work provides a robust data repository along with a web-based and user-friendly set of analysis tools to accelerate ACT development for solid tumors.

5 March 2026 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
JDJie Deng
Jie Deng
APAastha Pal
Aastha Pal
STStefano Testa
Stefano Testa
JXJingyu W. Xu
Jingyu W. Xu
LTLinh M. Tran
Linh M. Tran
AKAnusha Kalbasi
Anusha Kalbasi
Neoadjuvant immune checkpoint blockade (ICB) and radiotherapy (RT) improve disease-free survival in select patients with soft-tissue sarcoma (STS). However, most STS are myeloid-rich and lack preexisting T cells associated with ICB response. In preclinical models, we observed that intratumoral BO-112 [nanoplexed polyinosinic: polycytidylic acid (poly I:C)] engages myeloid cells that persist after RT, ultimately enhancing T cell–dependent tumor control. We evaluated BO-112 and hypofractionated RT, with or without nivolumab, in 14 patients with high-risk STS in a phase I neoadjuvant trial. Consistent with its immunologic potency, the triple combination induced rare immune-related adverse events (myositis–myocarditis–myasthenia gravis spectrum), mitigated by BO-112 and nivolumab dose adjustment. BO-112 and RT reprogrammed tumor-associated myeloid cells toward antigen-presenting states, promoted clonal replacement by less exhausted T cells, and enhanced malignant cell depletion compared with standard RT. These immunologic changes coincided with encouraging disease control in a small, high-risk cohort, supporting further clinical development. Significance: Intratumoral BO-112 and hypofractionated RT activate systemic T-cell immunity in mouse models and in a phase I neoadjuvant study of high-risk, resectable sarcoma. Engaging myeloid cells with BO-112 represents a potent strategy with RT to replete T cell–deficient tumors and expand the benefits of neoadjuvant ICB.

1 July 2026
Verified
Other
Open access
JDJie Deng
Jie Deng
APAastha Pal
Aastha Pal
STStefano Testa
Stefano Testa
JXJingyu W. Xu
Jingyu W. Xu
LTLinh M. Tran
Linh M. Tran
AKAnusha Kalbasi
Anusha Kalbasi
Supplementary Table S4 shows patient characteristics of surgical specimens from patients with sarcoma undergoing routine standard of care (n=44).

1 July 2026
Verified
Other
Open access
JDJie Deng
Jie Deng
APAastha Pal
Aastha Pal
STStefano Testa
Stefano Testa
JXJingyu W. Xu
Jingyu W. Xu
LTLinh M. Tran
Linh M. Tran
AKAnusha Kalbasi
Anusha Kalbasi
Supplementary Table S2 shows patient characteristics of 14 patients enrolled in an exploratory Phase 1 clinical trial to evaluate the safety of integrating intratumoral BO-112 with nivolumab and hypofractionated RT in the neoadjuvant setting for patients with resectable, high-risk soft tissue sarcoma (NCT04420975).


1 July 2026
Verified
Other
Open access
PDF file
JDJie Deng
Jie Deng
APAastha Pal
Aastha Pal
STStefano Testa
Stefano Testa
JXJingyu W. Xu
Jingyu W. Xu
LTLinh M. Tran
Linh M. Tran
AKAnusha Kalbasi
Anusha Kalbasi
Supplemental Figure S3 shows peripheral blood and serum analysis of patients in Cohort 0 with irAEs.